Can a Robot Be Trusted Inside a Virus Lab? The AI Evidence Says Not Yet
A preprint posted on 3 August 2026 teaches robots to read wet-lab protocols and act on them. Benchmarks published weeks earlier show why containment labs are still out of reach.
AI Latest dispatch
Claude can design proteins, but it can't help you study viruses
Anthropic published a wet-lab-validated protein binder result on 18 August 2026, then disclosed an 11-month biosecurity classifier gap. The two stories together explain why the world's most capable protein designer is also the one most locked out of virology.
More Observations
Everything else from the field.
ChatGPT's Training Trick Just Redesigned a Bird-Flu Vaccine Protein
A Nature Methods paper borrows the alignment method used to tune chatbots and applies it to protein design, producing a heat-stable H5N1 hemagglutinin with only 45 tries.
Could AI Have Called the Worst Ebola Outbreak in Years?
A new preprint tests whether computational and AI forecasting models could have predicted the 2026 Bundibugyo Ebola epidemic in DR Congo before it became one of the largest on record. Here is what the models got right, what they missed, and why it matters for outbreak science.
AI Discovered a Novel Drug Target; and Pharma Bought It
Genentech validated the first AI-discovered neuroscience drug target from its $12B Recursion partnership. A proof point the AI-drug discovery field needed.
When the Machines Start Doing Bioethics Too
The August 2026 American Journal of Bioethics issue confronts AI agents moving into clinical and research operations, and asks an uncomfortable question: what happens when those same agents start doing the work of bioethicists?
First mRNA flu vaccine wins FDA approval. A quiet revolution for pandemic preparedness
On 5 August 2026, the FDA approved Moderna's mFLUSIVA, the first mRNA seasonal flu vaccine. The decision is small in label and large in consequence, because the same platform that produced COVID-19 shots in months can now be redirected to a pandemic influenza strain in weeks.
AI Redesigned CRISPR's Molecular Scissors, and They Beat Nature's
Jennifer Doudna's lab used an AI protein-design model to build a synthetic gene-editing enzyme, SynTnpB, that edits human cells nearly twice as efficiently as the natural version. Here is what the Science paper actually shows, and what it does not.
Evolution as Training Data: How Biohub's Open Protein World Model Is Rewiring Drug Discovery
Biohub's open-source ESM models learned the rules of protein biology from evolution alone — and designed working drug binders in days. Here's what the release means, and where it falls short.
Could AI Replace Human Peer Reviewers? Rethinking Scientific Peer Review in the Age of AI
QED Science's AI ranked 57,455 bioRxiv preprints and named a 'top 1%'. Blinded experts sided with the machine over journal prestige in 75% of cases. We examine the evidence, the backlash, and what AI triage means for pandemic-era science.
AI Drug Discovery's Moment of Truth: A $2.75B Bet, Zero Approvals, and the Drug That Could Change Both
Eli Lilly just wagered up to $2.75 billion on AI-designed medicines, yet not one AI-discovered drug has full FDA approval. Here's why 2026 is the year the field finally gets tested against clinical reality.
The First AI-Designed Drug Just Entered Phase III. Here's What That Actually Proves.
Insilico Medicine has pushed rentosertib, a drug whose target and molecule were both generated by AI, into a pivotal Phase III trial. It's the clearest test yet of whether AI drug discovery can produce medicines that work, not just headlines.
Ebola Vaccine in 68 Days: Pandemic Speed Meets Reality
The first Bundibugyo Ebola vaccine reached human trials just 68 days into the DRC's largest-ever outbreak. What the sprint reveals about AI-era pandemic preparedness.
AI Designs Working Virus Genomes for the First Time
Stanford and Arc Institute researchers used genome language models to write complete bacteriophage genomes from scratch. Sixteen worked in the lab — and the result reopens a hard debate about AI biosecurity.
AI Foundation Model Maps Cancer Tissue: VirTues
VirTues, a new foundation model published in Nature, learns one shared representation of spatial proteomics data across marker panels and imaging platforms—and finds biomarkers that predict immunotherapy response.
Ebola's 100-Day Test: The Bundibugyo Vaccine Sprint
The Bundibugyo Ebola outbreak is now the largest in DRC history. With no licensed vaccine, three candidates have reached human trials in weeks — a real-world stress test of the 100 Days Mission, AI-assisted drug discovery and outbreak modelling.
AI vs. H5N1: How Artificial Intelligence Is Racing to Outsmart the Bird Flu Outbreak Sweeping Australia
Australia just logged its first H5N1 mass-mortality event. Here's how a new wave of AI tools — protein language models, generative antibody pipelines, AI-designed antigens — is being mobilised against the virus, and where the science still falls short.
The EU AI Act's Big Deadline Just Passed — and Drug Discovery Got a Reprieve
August 2, 2026 was supposed to be the day the EU AI Act's toughest rules hit high-risk systems. Then the Digital Omnibus moved the goalposts. Here's what actually changed, and what it means for AI in drug discovery.
AI Just Became the 16th Biodefense Priority. The Reason Is a DNA Order Form.
The Bipartisan Commission on Biodefense added AI as the first new technology priority to the Apollo Program since 2021. The technical evidence behind that decision comes from a red-team exercise in which AI-redesigned toxin sequences slipped past the screening software that DNA synthesis companies rely on.
57 Days From Emergency to First-in-Human — and What AI Actually Contributed
The 2026 Bundibugyo epidemic is now the largest Ebola outbreak ever recorded in the DRC, against a virus for which no licensed vaccine or therapy exists. It is also the first serious field test of AI-era biology's central promise — and the results are more sobering, and more interesting, than the hype allows.